On March 23, 2022, AutoBio’s SARS-CoV-2 Ag Rapid Home Test successfully passed the European clinical assessment and the audit of the notified institution, obtained the EU CE certificate. This certification indicates that the product can be sold in EU countries and countries that recognize EU CE certification.

AutoBio’s SARS-CoV-2 Ag Rapid Home Test adopts colloidal gold immunochromatography. People can collect their anterior nasal swabs for operation without testing equipment, and the test results can be obtained in about 15 minutes. The product is easy to operate with a short detection time. It can be applied in multiple scenarios, which can better meet the needs of home testing for epidemic prevention and control in the EU.

About Autobio Diagnostics Co., Ltd

Autobio specialized in R & D, production, marketing and service of clinical diagnostic products, especially covering immunoassay, microbiology and biochemistry fields. Meanwhile, Autobio is also actively planning the developments in the field of molecular diagnostics and provides a comprehensive solutions for medical laboratories. Autobio was listed on Shanghai Stock Exchange on September 1st, 2016, which is the first IVD manufacturer listed on the main board in Shanghai,China. In 2019, Autobio’s revenue achieved USD412 millions, a year-on-year increase of 38.85%; in 2020, Autobio’s revenue achieved USD459 millions.